Condition: HER2-positive Early-stage Breast Cancer · Sponsor: Rutgers, The State University of New Jersey
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Predictive Signature (HARPS) to identify HARPS-positive breast cancers. To assess 3-year invasive disease-free survival (iDFS) in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To correlate changes in ctDNA with treatment outcomes in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer. To understand the changes in quality of life (QOL) measure in patients with HARPS-positive HER2-positive breast cancer treated using an adaptive neoadjuvant trial design.
This description comes directly from the study's public registry record.
Mridula A George · 732-235-9692 · mridula@cinj.rutgers.edu
Always discuss trial participation with your own doctor first.
| RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center | Elizabeth, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Monmouth Medical Center | Long Branch, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Newark Beth Israel Medical Center | Newark, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset | Somerville, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Community Medical Center | Toms River, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07402473